进入8月份，资本市场板块轮动节奏显著加快，AI医疗公司市场关注度快速攀升，大有赶超此前热门的创新药板块之势。 从资金动向来看，机构调仓路径已清晰显现。截至6月底，多只此前重仓创新药的医疗主题基金、科技主题基金，纷纷对创新药标的进行减持甚至清仓操 作，并将释放出的仓位转向AI医疗领域个股，成为推动板块热度升温的重要力量。 长城久嘉创新成长基金经理龙宇飞指出，当前AI医疗赛道内多家公司业绩正逐步走出低谷、迈向触底回升通道，在市场资金阶段性"高低切换"的逻辑下，部 分资金有望从前期涨幅较高的板块，分流至估值位置相对较低、且未来一两年存在明确业务突破预期的AI医疗标的，该领域仍有不少具备成长潜力的公司 值得深入挖掘。 在市场节奏变换下，智云健康于近日发布2025年中期财报，释放出盈利能力大幅改善的信号。 作为中国最大的慢病数字化管理解决方案提供商，公司此前主动推进战略优化，果断收缩战略相关性较弱、盈利能力偏低的医疗用品及耗材销售类增值业 务，同时完成旗下若干家子公司的处置工作，将核心资源全面聚焦于AI赋能的P2M（从患者到工业）高价值赛道。 如今，2.0战略转型已逐步显现成效，智云健康经营正迈向良性循环，在当前AI医 ...

Core Insights - The emergence of the domestic AI model DeepSeek has sparked significant interest in the AI+ healthcare sector in China, with predictions of substantial industry growth by 2030 [1] - The AI healthcare market is expected to grow at an annual rate of 43% from 2024 to 2032, potentially reaching a market size of $491 billion [1] - The company Zhiyun Health is positioned as a leading provider of chronic disease management and healthcare solutions in Hong Kong, focusing on strategic upgrades and business optimization [1][2] Company Performance - Zhiyun Health reported total revenue of approximately 3.49 billion RMB, with a slight increase in gross margin to 24.7%, despite an expanded net loss due to the disposal of non-core businesses [2][4] - The company's core business, the hospital solution segment, has shown robust growth through its unique "Touch, Deploy, Commercialize" (AIM) model, with over 2,700 hospitals adopting its SaaS products [3][4] Strategic Initiatives - The "P2M" strategy has been implemented to enhance operational efficiency and optimize business structure, resulting in a significant increase in revenue from P2M solutions, which reached 320 million RMB, nearly doubling year-on-year [4][5] - The company has signed contracts with 45 pharmaceutical companies, with a total of 55 SKUs, indicating strong collaboration in the pharmaceutical sector [4] Market Environment - The healthcare industry is undergoing significant changes due to centralized procurement reforms, with price reductions of 20% to 30% expected for many common drugs, which may pressure traditional business models [2] - The AI+ healthcare market is projected to exceed 100 billion RMB by 2026, with a compound annual growth rate of over 30%, presenting a substantial growth opportunity for companies like Zhiyun Health [7] Technological Advancements - Zhiyun Health has developed two vertical models, ClouD GPT and ClouD DTx, which excel in patient interaction and medical research, contributing to a comprehensive digital chronic disease management service [7][8] - The integration of the DeepSeek-R1 model into the company's AI system aims to enhance chronic disease management efficiency by leveraging over 1 billion electronic medical records [8] Future Outlook - With ongoing policy support and technological innovation, the AI+ healthcare market in China is expected to thrive, providing a favorable environment for Zhiyun Health's growth [6][7] - The company's strategic focus on optimizing its business structure and enhancing its AI capabilities positions it well for sustained growth and increased market share in the evolving healthcare landscape [9]